- Alpha and beta emitters based radiopharmaceuticals are increasingly recognized for their precision in targeted therapy, especially in oncology and nuclear medicine, providing effective diagnosis and treatment options with minimal side effects
- The rising incidence of cancer worldwide, along with growing awareness about personalized medicine and advancements in radiopharmaceutical technology, is driving global demand for alpha and beta emitters based radiopharmaceuticals
- North America holds a significant share in the global alpha and beta emitters based radiopharmaceuticals market, accounting for approximately 42.59% share of the revenue in 2025, supported by advanced healthcare infrastructure, extensive R&D activities, and early adoption of novel therapeutic technologies
- North America region is anticipated to be the fastest-growing market for alpha and beta emitters based radiopharmaceuticals during the forecast period, propelled by expanding healthcare infrastructure, increasing cancer prevalence, government initiatives for healthcare improvement
- The beta emitters segment is expected to dominate the market with a share of 84.78% in 2025, driven by their high efficacy in Targeted Alpha Therapy (TAT), improved patient outcomes, and rising research focused on alpha-emitting isotopes like Actinium-225 and Radium-223 for cancer treatment
